Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 6 · 75%High 0 · 0%

All‐cause mortality · patients with hypertension

CCBs showed no clear difference in all‐cause mortality compared with diuretic (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
5 studies · 35057 participants
Moderate

All‐cause mortality · patients with hypertension

CCBs showed no clear difference in all‐cause mortality compared with ACE inhibitor (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.97 [0.91, 1.03]
7 studies · 27999 participants
Low

All‐cause mortality · patients with hypertension

CCBs showed no clear difference in all‐cause mortality compared with ARB (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1 [0.92, 1.08]
6 studies · 25611 participants
Moderate

All‐cause mortality · patients with hypertension

CCBs showed no clear difference in all‐cause mortality compared with β‐blocker (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.94 [0.88, 1]
4 studies · 44825 participants
Moderate

Cardiovascular mortality · patients with hypertension

CCBs may leads to lower cardiovascular mortality compared with β‐blocker (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.9 [0.81, 0.99]
4 studies · 44825 participants
Low

Cardiovascular mortality · patients with hypertension

CCBs showed no clear difference in cardiovascular mortality compared with ACE inhibitor (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.98 [0.89, 1.07]
6 studies · 27619 participants
Moderate

Cardiovascular mortality · patients with hypertension

CCBs showed no clear difference in cardiovascular mortality compared with ARB (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.79 [0.54, 1.15]
3 studies · 4642 participants
Moderate

Cardiovascular mortality · patients with hypertension

CCBs showed no clear difference in cardiovascular mortality compared with diuretic (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.02 [0.93, 1.12]
4 studies · 32721 participants
Moderate